Stocks of Enliven Therapeutics Inc (NASDAQ:ELVN) traded higher last session on Wall Street, up 0.84% to $21.68.
ELVN stock price is now -4.17% away from the 50-day moving average and -8.53% away from the 200-day moving average. The market capitalization of the company currently stands at $1.06B.
With the price target of $42, BTIG Research recently initiated with Buy rating for Enliven Therapeutics Inc (NASDAQ: ELVN). On September 09, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $37, while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, Patel Anish, Member of immediate family of bought 2,500 shares of the company’s stock on Feb 14 ’25. The stock was bought for $53,750 at an average price of $21.50. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 14 ’25, Member of immediate family of Patel Anish bought 2,500 shares of the business’s stock. A total of $53,750 was incurred on buying the stock at an average price of $21.50. A total of 36.87% of the company’s stock is owned by insiders.
During the past 12 months, Enliven Therapeutics Inc has had a low of $10.90 and a high of $30.03. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 17.44, and a quick ratio of 17.44. The fifty day moving average price for ELVN is $22.6231 and a two-hundred day moving average price translates $23.700874 for the stock.
The latest earnings results from Enliven Therapeutics Inc (NASDAQ: ELVN) was released for 2024-09-30.
